ImmunityBio, Inc. IBRX
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Wait for Q2 report in August before taking new positions
Strong revenue growth and regulatory expansion balance high burn rate and dilution risk, supporting the hold signal.
Predominantly positive on social media with focus on international expansion and sequential revenue growth, despite EPS miss from non-cash items.
HOLD is the call. Positive is the market mood. High risk means a lot can go wrong.
Latest change
- 5 Aug 2026 — Report issued 4 August shows sequential revenue growth and UAE approval as the drivers behind updated key figures.
About the company
ImmunityBio develops immunotherapies for cancer and infectious diseases. The lead product ANKTIVA is an IL-15 superagonist approved for non-muscle invasive bladder cancer in combination with BCG. The company is in early commercialization with strong revenue growth but continues to post large losses.
Bull case
Strong sequential ANKTIVA revenue growth and broader international approvals strengthen the commercial case.
Bear case
High operating burn rate and complex capital structure continue to drive large GAAP losses.
Why this signal
Strong revenue growth and regulatory expansion balance high burn rate and dilution risk, supporting the hold signal.
Recent news
Dr. Jim Yong Kim was appointed Vice Chairman in August to lead global expansion. ImmunityBio entered a partnership with Accord Healthcare for EU distribution and announced $100M financing of which $75M is non-dilutive. An FDA warning letter regarding promotional claims for ANKTIVA has been issued.